Convatec

12-Nov-24

Corporate

Financial Performance

Trading update for the ten months ended 31 October 2024

Convatec upgrades FY24 guidance; on-track for double-digit EPS growth in 2024 and 2025

21-Oct-24

Corporate

Infusion Care

Convatec collaborates with AbbVie for VYALEV™ therapy for the treatment of advanced Parkinson’s disease in the United States

Convatec’s Neria™ Guard will be used to deliver AbbVie’s VYALEV™ therapy (foscarbidopa and foslevodopa) in the United States, following FDA approval

10-Oct-24

Corporate

Advanced Wound Care

Convatec update on InnovaMatrix® AC clinical data – second randomised controlled trial authorised

Convatec continues to advance clinical evidence for InnovaMatrix® AC

20-Sep-24

Corporate

Advanced Wound Care

Convatec update on InnovaMatrix® AC clinical data

InnovaMatrix® AC is a pioneering technology in the treatment of wounds

01-Aug-24

Continence Care

Convatec me+ Companion™ App offers support for millions of intermittent catheter users

New free app offers users a practical tool to ensure their cathing journey starts smoothly

30-Jul-24

Corporate

Financial Performance

Interim Results for the six months ended 30 June 2024

Strong broad-based revenue growth and further strategic progress

26-Jul-24

Continence Care

Convatec’s pioneering catheter for women continues to scale up in Europe

The new compact offering blends gentle, protective cathing with everyday discretion and ease of use.

16-May-24

Corporate

Financial Performance

AGM trading update for the four months ended 30 April 2024

Revenue continued to build, further strategic progress, on track to deliver financial guidance

01-May-24

Advanced Wound Care

Convatec unveils significant advanced wound care clinical study results

New research demonstrates superiority of AQUACEL® Ag+ Extra™ dressing in the management of venous leg ulcers

06-Mar-24

Corporate

Financial Performance

Annual Results for the twelve months ended 31 December 2023